NAD+ delivery method selection depends on cellular goals, absorption mechanics, and lifestyle demands. Here is how clinicians choose between intravenous therapy and injectable protocols for metabolic optimization. ...
Supplement Notice: Berberine is a dietary supplement and is not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, or prevent any disease. It is not a substitute for prescription medications including metformin, semaglutide (Ozempic/Wegovy), or any other FDA-approved therapy. Berberine can interact with prescription medications including warfarin, cyclosporine, and metformin. Do not use berberine as a replacement for prescribed treatment without consulting your physician. Always seek the advice of a qualified healthcare provider before starting any supplement regimen.
Few supplements have had a more dramatic cultural moment than berberine. Once confined to the shelves of specialty health stores and the protocols of integrative medicine practitioners, berberine has become something of a phenomenon — propelled partly by social media comparisons to semaglutide (sold as Ozempic and Wegovy), a prescription GLP-1 receptor agonist that has transformed the treatment of type 2 diabetes and obesity. The comparison has a surface-level appeal. Both compounds influence metabolic pathways involved in blood sugar regulation. Both are discussed in the context of weight management. Berberine is a fraction of the cost, available without a prescription, and marketed across wellness channels as a "natural" alternative. The shorthand — "nature's Ozempic" — spread quickly and widely. The problem is that shorthand compresses a complicated evidence picture into a slogan. What the randomized controlled trial (RCT) evidence on berberine actually shows is more interesting — and more nuanced — than either its most enthusiastic proponents or its dismissers tend to acknowledge.
Image source: Envato[/caption]
A patient receives lab results from their doctor. The results are within normal ranges, and for many people, the conversation about their lab panel ends there. But normal on a standard lab report does not mean optimal, and the gap between those two things is where a significant amount of early metabolic dysfunction goes undetected.
Researchers and clinicians working in preventive and functional medicine have been examining how conventional reference ranges are constructed, what they actually measure, and whether they reliably catch early-stage dysfunction before it progresses to diagnosable disease. Practitioners in the field of lifestyle medicine frequently use this kind of deeper metabolic assessment as a foundation for early intervention, working with patients before markers reach the thresholds that trigger a clinical diagnosis.
Phase 3 SYNCHRONIZE-1 trial data shows survodutide achieves up to 16.6% average weight loss with targeted visceral fat reduction and significant liver fat improvements — presented at ADA 2026....
